SCHEMBL5165601

SCHEMBL5165601

CN(C)C1CCN(Cc2ccc(-c3ccc(O)cc3)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.56
LTA4H P09960 1/20 0.51
HRH3 Q9Y5N1 5/20 0.50
JAK2 O60674 1/20 0.48
CHRM4 P08173 1/20 0.47
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
BACE1 P56817 1/20 0.47
GRM2 Q14416 1/20 0.46
HRH2 P25021 1/20 0.44
HRH1 P35367 1/20 0.44
MELK Q14680 1/20 0.44
HSP90AA1 P07900 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM3 P20309 1/20 0.43
PARP1 P09874 1/20 0.43
PARP2 Q9UGN5 1/20 0.43
AXL P30530 1/20 0.43
MERTK Q12866 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164995 0.89 HDAC1 (0.53) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5165935 0.87 HDAC1 (0.63) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5166411 0.86 GRM2 (0.56) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5169216 0.85 HDAC1 (0.52) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5188483 0.84 LSS (0.52) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5191116 0.84 LSS (0.52) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5179140 0.84 HDAC1 (0.60) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL28626109 0.84 LTA4H (0.54) HDAC1LTA4HHRH3JAK2CHRM4
SCHEMBL5951793 0.82 HRH3 (0.67) HDAC1LTA4HHRH3HRH2HRH1
SCHEMBL5169162 0.82 HDAC1 (0.48) HDAC1LTA4HHRH3JAK2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014733-A1 Histamine-3 agonists and antagonists PFIZER INC 2006-01-19 US claimed
EP-1771438-A1 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP disclosed
WO-2006011042-A1 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO disclosed
US-20060014733-A1 Histamine-3 agonists and antagonists PFIZER INC 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014733-A1 Histamine-3 agonists and antagonists HRH3, HRH4, HRH2 HDAC1 1532/4885LTA4H 395/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.